Home › Therapeutic areas › GI/Hepatology
GI/Hepatology (12 companies · 7 conditions)
Conditions
Companies
| Ticker | Company | Therapeutic areas | In GI/Hepatology | Lead stage | Programs |
|---|---|---|---|---|---|
| ABSI | Absci | DermatologyGI/Hepatology+1 | 1 | Phase 1 | 7 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 1 | Phase 2 | 3 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 2 | Approved | 6 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | 9 |
| DBVT | DBV Technologies | GI/HepatologyImmunology Rare | 1 | NDA Submitted | 3 |
| ETON | Eton Pharmaceuticals | GI/HepatologyMetabolic+1 Rare | 2 | Approved | 14 |
| FBRX | Forte Biosciences | DermatologyGI/Hepatology | 1 | Phase 2 | 3 |
| IMUX | Immunic | GI/HepatologyNeurology | 1 | Phase 3 | 4 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyOncology+1 Rare | 1 | Phase 2 | 7 |
| RARE | Ultragenyx Pharmaceutical | CardiovascularGI/Hepatology+2 Rare | 1 | Approved | 12 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 2 | Approved | 26 |
| VKTX | Viking Therapeutics | GI/HepatologyMetabolic+1 Rare | 1 | Phase 3 | 9 |
No companies match.